LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Handheld Mass Spectrometry Probe Identifies Clinically Relevant Bacteria

By LabMedica International staff writers
Posted on 04 Oct 2022
Image: The MasSpec Pen, a handheld mass spectrometry-based device, enables rapid analysis of biological samples, including clinically relevant bacteria (Photo courtesy of Vivian Abagiu/University of Texas)
Image: The MasSpec Pen, a handheld mass spectrometry-based device, enables rapid analysis of biological samples, including clinically relevant bacteria (Photo courtesy of Vivian Abagiu/University of Texas)

Rapid identification of bacteria is critical to prevent antimicrobial resistance and ensure positive patient outcomes. Identifying bacteria while a patient is still in surgery could allow doctors to more quickly move to a targeted antibiotic for their infection.

The Handheld Mass Spectrometry Probe consists of a handheld, disposable ionization device connected to a mass spectrometer. It works via ambient ionization, using drops of water to extract lipids and metabolites from tissue that are then analyzed via mass spectrometry to generate molecular profiles. These can be used to distinguish between different tissue types or, in the case of a recent study, different bacteria.

Medical Scientists at The University of Texas at Austin (Austin, TX, USA) and their colleagues used the MasSpec Pen (Genio Technologies, Jordan, UT, USA) on cultured samples to generate molecular profiles and develop classifiers. They analyzed 163 culture samples comprising 28 strains across eight bacterial species, including Staphylococcus aureus, Group A and B Streptococcus, and Kingella kingae. The effort focused on microorganisms commonly linked to pediatric osteoarticular infections. The system currently uses a Thermo Fisher Orbitrap Exploris 120 mass spectrometer (Thermo Fisher Scientific, Waltham MA, USA) and comes packaged as a mobile, battery-powered device that can be moved between different operating rooms.

The team then then tested these classifiers in a validation set consisting of 74 samples spanning 15 strains. In the validation work, they found that the pen was able to distinguish between Group A and B Streptococcus with 85% accuracy and between S. aureus and Staphylococcus epidermidis with 97% accuracy. The device identified a validation set of 24 samples of Gram-negative bacteria spanning six strains with accuracy of 92%. They then applied their classifiers to a set of five clinical samples taken from four patients with osteoarticular infections, exploring how the device performed in direct surgical specimens without culture. They were not able to identify the bacteria down to the species level, but were able to identify the Gram stain type and genus of the microbes in the different samples.

Livia Eberlin, PhD, associate professor of surgery and inventor of the MasSpec Pen, said, “We're centered in surgical applications, and one of the things we've been asked by a variety of surgeons, especially infectious disease surgeons, is whether we could identify bacteria when we were excising, for instance, infected bone.”

The authors concluded that the MasSpec Pen enables identification of several bacteria at different taxonomic levels in seconds from cultured samples and has potential for culture-independent identification of bacteria directly from clinical samples based on the detection of metabolic species. The study was published on September 14, 2022 in the journal Clinical Chemistry.

Related Links:
The University of Texas at Austin 
Genio Technologies 
Thermo Fisher Scientific 

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Automated MALDI-TOF MS System
EXS 3000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more